Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4)

Conclusions. In individuals with controlled VL on a boosted PI regimen who switched to RAL, none of the endpoints differed with nonswitchers after IPTW.

Source: Clinical Infectious Diseases - October 13, 2016 Category: Infectious Diseases Authors: Potard, V., Simon, A., Lacombe, J.-M., Parienti, J.-J., Costagliola, D., for the French Hospital Database on HIV (FHDH-ANRS CO4) Tags: HIV/AIDS Source Type: research